Research Studies

Largest Study To-Date Confirms NIVH Therapy Improves Mortality Risk and Reduces Healthcare Costs in Hypercapnic COPD-CRF Patients

Online Edition of Respiratory Medicine (JUNE 29, 2022) 

"Early Initiation of NIVH Therapy Improves Survival and Reduces Healthcare costs in COPD Patients with Chronic Hypercapnic Respiratory Failure: A Retrospective Cohort Study," William D. Frazier, MD, Joan E. DaVanzo, Allen Dobson, Steven Heath, Komi Mati

Study Highlights

  • The most extensive research to date utilizes 500,000+ claims from Medicare patients (2016-2020).
  • First of its kind, peer-reviewed study correlates healthcare cost-savings with the timing of treatment initiation for hypercapnic COPD-CRF patients.
  • Reinforces previous findings that the faster NIVH therapy begins, the greater the mortality and hospitalization reductions.

Cost Savings Analysis

0 - 7 days

$5,484 (11.6% reduction)

0 - 15 days

$3,412 (7.2% reduction)

15+ days

Cost Neutral

Mortality Reduction

0-7 days
8-15 days
13-30 days

William Frazier, MD

Chief Medical Officer, VieMed

"The clinical and financial benefits of NIVH are greatest when therapy begins immediately after diagnosis."

For more information about this study and how VieMed can help your patients, please call 866-852-8343.

Additional Research and Resources

NIVH Treatment Webinar Replay

In this December 2021 Webinar, board-certified Pulmonologist and VieMed’s Chief Medical Officer, Dr. William D. Frazier discusses peer-reviewed medical studies about the impact of NIVH on both patients and the US healthcare system.